Literature DB >> 18547298

Managing intentions: the end-of-life administration of analgesics and sedatives, and the possibility of slow euthanasia.

Charles Douglas1, Ian Kerridge, Rachel Ankeny.   

Abstract

There has been much debate regarding the 'double-effect' of sedatives and analgesics administered at the end-of-life, and the possibility that health professionals using these drugs are performing 'slow euthanasia.' On the one hand analgesics and sedatives can do much to relieve suffering in the terminally ill. On the other hand, they can hasten death. According to a standard view, the administration of analgesics and sedatives amounts to euthanasia when the drugs are given with an intention to hasten death. In this paper we report a small qualitative study based on interviews with 8 Australian general physicians regarding their understanding of intention in the context of questions about voluntary euthanasia, assisted suicide and particularly the use of analgesic and sedative infusions (including the possibility of voluntary or non-voluntary 'slow euthanasia'). We found a striking ambiguity and uncertainty regarding intentions amongst doctors interviewed. Some were explicit in describing a 'grey' area between palliation and euthanasia, or a continuum between the two. Not one of the respondents was consistent in distinguishing between a foreseen death and an intended death. A major theme was that 'slow euthanasia' may be more psychologically acceptable to doctors than active voluntary euthanasia by bolus injection, partly because the former would usually only result in a small loss of 'time' for patients already very close to death, but also because of the desirable ambiguities surrounding causation and intention when an infusion of analgesics and sedatives is used. The empirical and philosophical implications of these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18547298     DOI: 10.1111/j.1467-8519.2008.00661.x

Source DB:  PubMed          Journal:  Bioethics        ISSN: 0269-9702            Impact factor:   1.898


  8 in total

1.  Accessing the ethics of complex health care practices: would a "domains of ethics analysis" approach help?

Authors:  Jeffrey Kirby
Journal:  HEC Forum       Date:  2010-06

2.  Palliative sedation, foregoing life-sustaining treatment, and aid-in-dying: what is the difference?

Authors:  Patrick Daly
Journal:  Theor Med Bioeth       Date:  2015-06

3.  Current debates on end-of-life sedation: an international expert elicitation study.

Authors:  Evangelia Evie Papavasiliou; Sheila Payne; Sarah Brearley
Journal:  Support Care Cancer       Date:  2014-03-20       Impact factor: 3.603

4.  Morally-Relevant Similarities and Differences Between Assisted Dying Practices in Paradigm and Non-Paradigm Circumstances: Could They Inform Regulatory Decisions?

Authors:  Jeffrey Kirby
Journal:  J Bioeth Inq       Date:  2017-10-05       Impact factor: 1.352

5.  Physician-Patient Relationship, Assisted Suicide and the Italian Constitutional Court.

Authors:  E Turillazzi; A Maiese; P Frati; M Scopetti; M Di Paolo
Journal:  J Bioeth Inq       Date:  2021-10-21       Impact factor: 1.352

6.  Reporting of euthanasia in medical practice in Flanders, Belgium: cross sectional analysis of reported and unreported cases.

Authors:  Tinne Smets; Johan Bilsen; Joachim Cohen; Mette L Rurup; Freddy Mortier; Luc Deliens
Journal:  BMJ       Date:  2010-10-05

7.  Questions and answers on the Belgian model of integral end-of-life care: experiment? Prototype? : "Eu-euthanasia": the close historical, and evidently synergistic, relationship between palliative care and euthanasia in Belgium: an interview with a doctor involved in the early development of both and two of his successors.

Authors:  Jan L Bernheim; Wim Distelmans; Arsène Mullie; Michael A Ashby
Journal:  J Bioeth Inq       Date:  2014-08-16       Impact factor: 1.352

8.  Decisions that hasten death: double effect and the experiences of physicians in Australia.

Authors:  Steven A Trankle
Journal:  BMC Med Ethics       Date:  2014-03-25       Impact factor: 2.652

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.